Anti-VP2 (a) and anti-VP4 (b) antibodies in cord blood serum of BABYDIAB study participants stratified as beta cell autoantibody negative throughout follow-up (no autoimmunity), beta cell autoantibody seroconversion before age 3 years with IAA as the first detected autoantibodies (early insulin), and beta cell autoantibody seroconversion with GAD as the first detected autoantibody target (GAD). Each point is an individual and the horizontal bar indicates the median. No significant differences based on comparison with early insulin autoimmunity group for the corresponding CVB serotype using the Mann Whitney U test.
Supplementary Figure 6: Maternal anti-CVB antibody profiles in newborns differ from those observed in adolescents.
The LIPS assay was used to detect antibodies to viral capsid protein (VP) antigens of CVB1-6 in cord blood serum (Newborn), healthy control children and adolescents (Healthy controls), and children and adolescents with recent onset type 1 diabetes (Recent onset T1D). (a) Antibody titers against VPs of CBV1-6 are represented as a heat map where each vertical line is a sample and the intensity of the color corresponds to the RLU measured by the LIPS assay. Data is sorted based on the clusters that were identified as described in Fig. 1. (b) The proportion of sera within the 4 clusters defined in Fig. 1 is represented by a stacked bar chart for each cohort.
A higher proportion of samples from newborns were observed in cluster 4 (p>0.001 Healthy controls; p=0.004 Recent onset T1D) and a lower proportion of samples from newborns were observed in cluster 1 (p=0.002 Healthy controls; p=0.027 Recent onset T1D) as compared to the children/adolescent groups using the Z-score test statistic and two-tailed test. 
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